ALRN NASDAQ
Aileron Therapeutics, Inc.
1W: +4.1%
1M: +0.0%
3M: -47.8%
1Y: -52.7%
3Y: -77.6%
5Y: -84.5%
$2.11
Last traded 2025-02-07 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$51M
+22.2% ▲
Net Income
-$50M
+20.7% ▲
EPS (Diluted)
$-1.96
+44.2% ▲
EBITDA
-$51M
+22.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $121K | $169K | $119K | $0 | $0 |
| Gross Profit | -$121K | -$169K | -$119K | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $17M | $18M | $4M | $14M | $11M |
| SG&A Expenses | $10M | $10M | $11M | $14M | $11M |
| Operating Expenses | $27M | $28M | $16M | $65M | $51M |
| Operating Income | -$27M | -$28M | -$16M | -$65M | -$51M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$26M | -$27M | -$16M | -$63M | -$50M |
| Tax Expense | -$441K | $0 | $0 | $0 | $0 |
| Net Income | -$26M | -$27M | -$16M | -$63M | -$50M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-5.80 | $-5.95 | $-3.42 | $-3.51 | $-1.96 |
| EBITDA | -$26M | -$27M | -$16M | -$65M | -$51M |
| Shares Outstanding | 4M | 5M | 5M | 18M | 25M |